Estrella Immunopharma, Inc. ESLA
0.48
0.01
2.13%
as of 25 Sep
- Market cap
- $20.5M
- P/E
- 0.0×
Follow ESLA
| Dec '25 | Dec '24 | Jun '24 | Jun '23 | Dec '22 | Jan '22 | Dec '21 | Jun '21 | Jan '21 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.12 | 0.55 | 24.65 | 0.28 | 0.05 | 0.05 | 8.42 | 0.00 | 8.42 | — |
Net Debt/EBITDA |
0.11 | 0.21 | 0.57 | 0.22 | (0.29) | (0.29) | 1.92 | 0.00 | 1.92 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 5.13% | 4.99% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | (0.22) | 0.07 | 0.00 | — | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.14 | 0.70 | 2.20 | 0.12 | 3.39 | 1.05 | 0.18 | 0.01 | 1.28 | — |
Capex/Depreciation |
— | — | — | — | — | — | — | 0.00 | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| 255.59% | (200.44%) | 195.79% | 158.80% | (12.78%) | (32.85%) | (8.30%) | 0.00% | (1.15%) | — | |
| (413.55%) | (116.58%) | (195.43%) | (174.31%) | (3.12%) | (3.57%) | (7.83%) | (1.08%) | (1.08%) | — | |
ROIC |
0.00% | 0.00% | (4,226.47%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
110.09% | 326.43% | (171.09%) | 158.64% | 30.16% | 97.59% | (330.20%) | (180.54%) | (45.63%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | — | — | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | — | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | — | — | — | — | — |
Free Cash Flow per Share |
(0.05) | (0.09) | (0.59) | (4.37) | (0.74) | (0.18) | (0.27) | 0.00 | (0.05) | — |
Cash per Share |
0.04 | 0.03 | 0.15 | 8.11 | 0.03 | 0.01 | 0.41 | — | 0.08 | — |
Shareholders Equity per Share |
(0.28) | 0.00 | 0.16 | (22.06) | (1.59) | 1.23 | (0.85) | — | 7.55 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Book value per Share |
(0.28) | 0.00 | 0.16 | (22.06) | (1.59) | 1.23 | (0.85) | — | 7.55 | — |
Free Cash Flow |
(1.79) | (3.11) | (16.07) | (1.34) | (1.04) | (1.04) | (0.32) | 0.00 | (0.32) | — |
Working Capital |
(11.87) | (1.36) | 4.27 | (7.01) | (1.02) | (1.02) | 0.54 | 0.14 | 0.54 | — |
Capital Expenditures |
— | — | — | — | — | — | — | 0.00 | — | — |
Net Current Asset Value |
(11.87) | (1.36) | 4.27 | (7.02) | (11.93) | (2.86) | (46.19) | 0.14 | (1.01) | — |
| Other line items | ||||||||||
Quick Ratio |
0.10 | 0.31 | 23.05 | 0.25 | 0.04 | 0.04 | 6.54 | — | 6.54 | — |
Depreciation/Fixed assets |
— | — | — | — | — | — | — | 0.00 | — | — |
Cash ROIC |
19.88% | (293.56%) | (190.41%) | 31.34% | 60.82% | (13.72%) | 59.97% | 0.00% | (0.71%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | — | 0.00 | 0.00 | — | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Operating CF per Share |
(0.05) | (0.09) | (0.59) | (4.37) | (0.74) | (0.18) | (0.27) | 0.00 | (0.05) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
0.28 | 4.67 | — | 4.83 | 0.17 | — | — | — | — | — |
Average Assets |
3.16 | 3.80 | 3.74 | 6.38 | 9.86 | 27.90 | 22.90 | 22.90 | 22.90 | — |
Average Common Equity |
(5.11) | 2.21 | (3.73) | (7.00) | 2.41 | 3.03 | 21.59 | — | 21.59 | — |
Capex to Sales |
— | — | — | — | — | — | — | 0.00 | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates